Comparison between GRAAPH-2003 and LALA-94 studies
| . | Present GRAAPH-2003 . | LALA-94 . | P . |
|---|---|---|---|
| No. patients | 45 | 198 | |
| Hematologic CR, no./no. patients tested (%) | |||
| All patients | 43/45 (96) | 140/198 (71) | <.001 |
| Chemoresistant patients* | 24/25 (96) | 63/105 (60) | <.001 |
| Allogeneic transplantation rate, no./no. patients tested (%) | |||
| All CR patients | 22/43 (51) | 62/140 (44) | .49 |
| CR patients with a donor | 22/22 (100) | 62/73 (85) | .06 |
| Cumulative incidence of relapse: 18-mo estimates, % (95% CI) | 30 (15-57) | 49 (40-59) | .02 |
| DFS: 18-mo estimates, % (95% CI) | 51 (29-69) | 31 (24-39) | .02 |
| Overall survival: 18-mo estimates, % (95% CI) | 65 (43-81) | 39 (32-46) | .05 |
| . | Present GRAAPH-2003 . | LALA-94 . | P . |
|---|---|---|---|
| No. patients | 45 | 198 | |
| Hematologic CR, no./no. patients tested (%) | |||
| All patients | 43/45 (96) | 140/198 (71) | <.001 |
| Chemoresistant patients* | 24/25 (96) | 63/105 (60) | <.001 |
| Allogeneic transplantation rate, no./no. patients tested (%) | |||
| All CR patients | 22/43 (51) | 62/140 (44) | .49 |
| CR patients with a donor | 22/22 (100) | 62/73 (85) | .06 |
| Cumulative incidence of relapse: 18-mo estimates, % (95% CI) | 30 (15-57) | 49 (40-59) | .02 |
| DFS: 18-mo estimates, % (95% CI) | 51 (29-69) | 31 (24-39) | .02 |
| Overall survival: 18-mo estimates, % (95% CI) | 65 (43-81) | 39 (32-46) | .05 |
CI indicates confidence interval.
Considering that early treatments were different in both studies (no prephase, no L-asparaginase, different anthracycline types and dosages in the LALA-94 trial).